Skip to main content
Fig. 9 | The Journal of Headache and Pain

Fig. 9

From: Galcanezumab effects on incidence of headache after occurrence of triggers, premonitory symptoms, and aura in responders, non-responders, super-responders, and super non-responders

Fig. 9

Galcanezumab effects on incidence of triggers that were followed by headache in responders and non-responders. A Incidence of all triggers that were followed by headache after galcanezumab treatment decreased in both, responders and non-responders. Note that after occurrence of, or exposure to triggers, responders experienced significantly less headaches than non-responders (p = 0.0001, DF = 1, Fisher exact). B Incidences of headache following occurrence of, or exposure to each trigger during the 3-month treatment period. The 100% (in A and B) represents incidences of all (A) and individual (B) premonitory symptoms that were followed by headache prior to treatment initiation

Back to article page